150 related articles for article (PubMed ID: 38204220)
21. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
[TBL] [Abstract][Full Text] [Related]
22. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.
Wan YL; Zheng SS; Zhao ZC; Li MW; Jia CK; Zhang H
World J Gastroenterol; 2004 Jan; 10(2):195-9. PubMed ID: 14716821
[TBL] [Abstract][Full Text] [Related]
23. Intrahepatic inflammatory IgA
Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
[TBL] [Abstract][Full Text] [Related]
24. The neurotrophic tyrosine kinase receptor 1 (TrkA) is overexpressed in oesophageal squamous cell carcinoma.
Griffin N; Gao F; Jobling P; Oldmeadow C; Wills V; Walker MM; Faulkner S; Hondermarck H
Pathology; 2021 Jun; 53(4):470-477. PubMed ID: 33143904
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
26. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
27. GOLM1 exacerbates CD8
Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX
Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203
[TBL] [Abstract][Full Text] [Related]
28. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.
Hu Z; Chen G; Zhao Y; Gao H; Li L; Yin Y; Jiang J; Wang L; Mang Y; Gao Y; Zhang S; Ran J; Li L
Mol Cancer; 2023 Mar; 22(1):55. PubMed ID: 36932387
[TBL] [Abstract][Full Text] [Related]
29. Distribution and relative density of p75 nerve growth factor receptors in the rat brain as a function of age and treatment with antibodies to nerve growth factor.
Urschel BA; Hulsebosch CE
Brain Res; 1992 Sep; 591(2):223-38. PubMed ID: 1446237
[TBL] [Abstract][Full Text] [Related]
30. Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.
Tan Y; Yang S; Ma Y; Li J; Xie Q; Liu C; Zhao Y
Int J Nanomedicine; 2021; 16():3241-3254. PubMed ID: 34007176
[TBL] [Abstract][Full Text] [Related]
31. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
32. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
34. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
35. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
[TBL] [Abstract][Full Text] [Related]
36. Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components.
Tokusashi Y; Asai K; Tamakawa S; Yamamoto M; Yoshie M; Yaginuma Y; Miyokawa N; Aoki T; Kino S; Kasai S; Ogawa K
Int J Cancer; 2005 Mar; 114(1):39-45. PubMed ID: 15523689
[TBL] [Abstract][Full Text] [Related]
37. Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model.
Yu L; Liu Q; Huo J; Wei F; Guo W
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):36-40. PubMed ID: 32415924
[TBL] [Abstract][Full Text] [Related]
38. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive CD10
Meng Y; Ye F; Nie P; Zhao Q; An L; Wang W; Qu S; Shen Z; Cao Z; Zhang X; Jiao S; Wu D; Zhou Z; Wei L
J Hepatol; 2023 Dec; 79(6):1435-1449. PubMed ID: 37689322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
